BioMed Research International / 2015 / Article / Tab 1

Review Article

Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials

Table 1

Baseline characteristics of included studies.

Study YearInterventionsOutcomesJadad score
(Ver.) (Dil.) (Con.) Expt.Ctrl.

Taniyama et al. [16] 199720 0200.5 mg verapamil
(diluted in 10 mL saline)
120 mg po follow-up study
BlankTIMI/LVEF/WMI3
Vijayalakshmi et al. [19] 2006 49 0500.5 mg verapamil HeparinizedTIMI/MACE/TFC/WMI3
Hendler et al. [20] 200610 010 0.5 mg verapamilHeparinizedTIMI/LVEF2
Chang et al. [21] 201029 035100–400 g verapamilNitroglycerin CTFC2
Huang et al. [22] 2012343434200 g verapamil (max 1 mg)
400 g diltiazem (max 1 mg)
Nitroglycerin
(max 1 mg)
TIMI/CTFC/LVEF/MACE3
Li et al. [23] 2012 04039Diltiazem 90 mg bid/6 monthsPlaceboTIMI/CTFC/LVEF/MACE6
Ozdogru et al. [24] 2013 030 305 mg diltiazemNitroglycerinCTFC/HR/BP2
Akturk et al. [25] 201415015VerapamilPlaceboCTFC/LEVF2
Overall 157104233